Food, Drugs, Healthcare, Life Sciences

A federal district court has ruled that the Employee Retirement Income Security Act (ERISA) preempts a state's "any willing provider" (AWP) law as applied to self-insured health plans.

In its effort to ensure the ongoing quality, safety, nutritional adequacy, and resilience of the domestic infant formula supply, the U.S. Department of Health and Human Services (HHS)...

Following the announcement that four Center for Medicare and Medicaid Innovation (CMMI or Innovation Center) models will end in 2025, the Centers for Medicare & Medicaid Services...

Headquartered in India, ABC Group (Client) is present in diversified businesses with a strong foothold in pharmaceuticals, biotechnology, and packaging industries.

In its effort to ensure the ongoing quality, safety, nutritional adequacy, and resilience of the domestic infant formula supply, the U.S. Department of Health and Human Services (HHS)...

Life sciences employers have been impacted by various market forces in the last several years, and the recent economic turbulence is only adding to the challenges they face.

A federal district court has ruled that the Employee Retirement Income Security Act (ERISA) preempts a state's "any willing provider" (AWP) law as applied to self-insured health plans.

In a recent move to ensure food safety and quality, the Food Safety and Standards Authority of India (FSSAI) has issued a notification...

Following up on Donald Trump's May 12 Executive Order on Most Favored Nation Prescription Drug Pricing (see our post here), The Department of Health...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.